English

PANDION THERAPEUTICS, INC.

EDGAR

PAND Report (type unavailable) · filed 2021-03-31

5 filing records in this dataset, filed from 2020-06-26 to 2021-03-31. Reported financial figures are available; chart coverage varies by period.

Inspect reported changes Compare with another company Historical disclosures Search filings Segments

Watchlist

Latest quarter

Revenue

2.19 million USD

2020 Q4 · USD

Exact inputs and evidence

Revenue: 8779000 USD Source
Revenue: 6588000 USD Source

Operating margin

-512.51%

2020 Q4 · %

Exact inputs and evidence

Operating Income: -37929000 USD Source
Operating Income: -26700000 USD Source
Revenue: 8779000 USD Source
Revenue: 6588000 USD Source

Operating cash flow

-11.2 million USD

2020 Q4 · USD

Exact inputs and evidence

Operating Cash Flow: -34988000 USD Source
Operating Cash Flow: -23821000 USD Source

Free cash flow

-12 million USD

2020 Q4 · USD

Exact inputs and evidence

Operating Cash Flow: -34988000 USD Source
Operating Cash Flow: -23821000 USD Source
Capital Expenditure: 2788000 USD Source
Capital Expenditure: 2005000 USD Source

Cash and cash equivalents: 220 million USD 2020-12-31 Source
Exact value

219891000 USD
Long-term debt including current maturities: Not available
Shares outstanding: 28.4 million shares 2020-12-31 Source
Exact value

28381893 shares

Reported share-count change

2,455.16% · 27.3 million shares

Year-over-year change in reported shares. Splits, issuance and buybacks can affect this figure; it does not isolate employee compensation or economic dilution.

Exact inputs and evidence

1110767 shares · 2019-12-31· Source
28381893 shares · 2020-12-31· Source

Includes later revisions to earlier periods. Annual charts exclude incomplete years.

Latest filing recorded: 2021-03-31.

Financial data available through: 2020-12-31.

Coverage by financial measure

Revenue: 2 of 11 periods available· newest 2020-12-31
Operating income: 2 of 11 periods available· newest 2020-12-31
Net income: 2 of 11 periods available· newest 2020-12-31
Operating cash flow: 2 of 11 periods available· newest 2020-12-31
Capital expenditure: 2 of 11 periods available· newest 2020-12-31
Total assets: 2 of 11 periods available· newest 2020-12-31
Total liabilities: 2 of 11 periods available· newest 2020-12-31
Current assets: 2 of 11 periods available· newest 2020-12-31
Current liabilities: 2 of 11 periods available· newest 2020-12-31
Cash and cash equivalents: 2 of 11 periods available· newest 2020-12-31
long term debt: No compatible figures in this window
Shares outstanding: 2 of 11 periods available· newest 2020-12-31

Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.

What changed year over year

Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.

Revenue
+807.9%

Prior period

USD 967,000

2019-01-01 – 2019-12-31
Current period

USD 8.78 million

2020-01-01 – 2020-12-31

Exact inputs and evidence

8779000 − 967000 = 7812000 USD

967000 USD · 2019-01-01 – 2019-12-31
Inspect prior input Prior source
8779000 USD · 2020-01-01 – 2020-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Revenue · PANDION THERAPEUTICS, INC. · 2020-12-31 PANDION THERAPEUTICS, INC. (edgar:1807901) Year-over-year change in Revenue: 7812000 USD Concept: fundies:Revenue Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T11:36:18Z Snapshot: 1432ffc521b4693c9c45bf2e8bd12bb6a43540b1617f7c3516e4ba0de06096a1 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1807901?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:Revenue: 8779000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1807901/000156459021012895/pand-20201231.xml#152107 Filing: 000156459021012895 Input fundies:Revenue: 967000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1807901/000156459021012895/pand-20201231.xml#152335 Filing: 000156459021012895
The citation records this snapshot. The page link may show a newer release later.
Net income
−USD 16.23 million

Prior period

−USD 21.88 million

2019-01-01 – 2019-12-31
Current period

−USD 38.11 million

2020-01-01 – 2020-12-31

Exact inputs and evidence

-38105000 − -21877000 = -16228000 USD

-21877000 USD · 2019-01-01 – 2019-12-31
Inspect prior input Prior source
-38105000 USD · 2020-01-01 – 2020-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Net income · PANDION THERAPEUTICS, INC. · 2020-12-31 PANDION THERAPEUTICS, INC. (edgar:1807901) Year-over-year change in Net income: -16228000 USD Concept: fundies:NetIncome Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T11:36:18Z Snapshot: 1432ffc521b4693c9c45bf2e8bd12bb6a43540b1617f7c3516e4ba0de06096a1 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1807901?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:NetIncome: -38105000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1807901/000156459021012895/pand-20201231.xml#155000 Filing: 000156459021012895 Input fundies:NetIncome: -21877000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1807901/000156459021012895/pand-20201231.xml#155154 Filing: 000156459021012895
The citation records this snapshot. The page link may show a newer release later.
Operating cash flow
−USD 21.56 million

Prior period

−USD 13.43 million

2019-01-01 – 2019-12-31
Current period

−USD 34.99 million

2020-01-01 – 2020-12-31

Exact inputs and evidence

-34988000 − -13429000 = -21559000 USD

-13429000 USD · 2019-01-01 – 2019-12-31
Inspect prior input Prior source
-34988000 USD · 2020-01-01 – 2020-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Operating cash flow · PANDION THERAPEUTICS, INC. · 2020-12-31 PANDION THERAPEUTICS, INC. (edgar:1807901) Year-over-year change in Operating cash flow: -21559000 USD Concept: fundies:OperatingCashFlow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T11:36:18Z Snapshot: 1432ffc521b4693c9c45bf2e8bd12bb6a43540b1617f7c3516e4ba0de06096a1 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1807901?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:OperatingCashFlow: -34988000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1807901/000156459021012895/pand-20201231.xml#181115 Filing: 000156459021012895 Input fundies:OperatingCashFlow: -13429000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1807901/000156459021012895/pand-20201231.xml#181327 Filing: 000156459021012895
The citation records this snapshot. The page link may show a newer release later.
Capital expenditure
+339.1%

Prior period

USD 635,000

2019-01-01 – 2019-12-31
Current period

USD 2.79 million

2020-01-01 – 2020-12-31

Exact inputs and evidence

2788000 − 635000 = 2153000 USD

635000 USD · 2019-01-01 – 2019-12-31
Inspect prior input Prior source
2788000 USD · 2020-01-01 – 2020-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Capital expenditure · PANDION THERAPEUTICS, INC. · 2020-12-31 PANDION THERAPEUTICS, INC. (edgar:1807901) Year-over-year change in Capital expenditure: 2153000 USD Concept: fundies:CapitalExpenditure Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T11:36:18Z Snapshot: 1432ffc521b4693c9c45bf2e8bd12bb6a43540b1617f7c3516e4ba0de06096a1 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1807901?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:CapitalExpenditure: 2788000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1807901/000156459021012895/pand-20201231.xml#181539 Filing: 000156459021012895 Input fundies:CapitalExpenditure: 635000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1807901/000156459021012895/pand-20201231.xml#181749 Filing: 000156459021012895
The citation records this snapshot. The page link may show a newer release later.

Where revenue goes

How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.

2020 2020-01-01 – 2020-12-31

Revenue USD 8.78 million 100% of revenue
Operating costs Derived USD 46.71 million 532% of revenue
Operating income −USD 37.93 million −432% of revenue
Tax, interest and other Derived USD 176,000 2% of revenue
Net income −USD 38.11 million −434% of revenue

Cash

Operating cash flow −USD 34.99 million −399% of revenue
Capital expenditure USD 2.79 million 32% of revenue
Free cash flow Derived −USD 37.78 million −430% of revenue

Share of revenue by period

Net income
Tax, interest and other
Operating costs

2019 Operating loss: operating costs were 2,398% of revenue.
2020 Operating loss: operating costs were 532% of revenue.

Values and sources

Revenue breakdown by annual reporting period
Period	Revenue	Operating costs	Operating income	Tax, interest and other	Net income	Free cash flow	Source
2019 2019-01-01 – 2019-12-31	967000	23186000 Derived	-22219000	-342000 Derived	-21877000	-14064000 Derived	Source 2019-01-01 – 2019-12-31: 967000 USD Inspect Revenue Open source 2019-01-01 – 2019-12-31: -22219000 USD Inspect Operating Income Open source 2019-01-01 – 2019-12-31: -21877000 USD Inspect Net Income Open source 2019-01-01 – 2019-12-31: -13429000 USD Inspect Operating Cash Flow Open source 2019-01-01 – 2019-12-31: 635000 USD Inspect Capital Expenditure Open source
2020 2020-01-01 – 2020-12-31	8779000	46708000 Derived	-37929000	176000 Derived	-38105000	-37776000 Derived	Source 2020-01-01 – 2020-12-31: 8779000 USD Inspect Revenue Open source 2020-01-01 – 2020-12-31: -37929000 USD Inspect Operating Income Open source 2020-01-01 – 2020-12-31: -38105000 USD Inspect Net Income Open source 2020-01-01 – 2020-12-31: -34988000 USD Inspect Operating Cash Flow Open source 2020-01-01 – 2020-12-31: 2788000 USD Inspect Capital Expenditure Open source

Amounts are exact, in USD.

Growth

Sales over time and how quickly they are changing.

Revenue

Revenue reported for each complete financial period.

USD 8.8M 2020

Values and sources

Revenue values and source evidence
Period	Series	Value(USD)	Source evidence
20192019-12-31	Revenue	967000	Revenue: 967000 Open source
20202020-12-31	Revenue	8779000	Revenue: 8779000 Open source

Revenue growth

Change in revenue from the same financial period one year earlier.

807.9% 2020

Values and sources

Revenue growth values and source evidence
Period	Series	Value	Source evidence
20192019-12-31	Year over year	No prior comparable period	Revenue: 967000 Open source
20202020-12-31	Year over year	807.9%	Revenue: 8779000 Open source Revenue: 967000 Open source

Profit and cash

How much revenue becomes profit, and how much cash operations generate.

Profit margins

Operating income, net income and free cash flow as a share of revenue.

Operating margin -432% 2020

Net margin -434% 2020

Free cash flow margin -430.3% 2020

Operating margin
Net margin
Free cash flow margin

Values and sources

Profit margins values and source evidence
Period	Series	Value	Source evidence
20192019-12-31	Operating margin	-2,297.7%	Operating Income: -22219000 Open source Revenue: 967000 Open source
20202020-12-31	Operating margin	-432%	Operating Income: -37929000 Open source Revenue: 8779000 Open source
20192019-12-31	Net margin	-2,262.4%	Net Income: -21877000 Open source Revenue: 967000 Open source
20202020-12-31	Net margin	-434%	Net Income: -38105000 Open source Revenue: 8779000 Open source
20192019-12-31	Free cash flow margin	-1,454.4%	Revenue: 967000 Open source Operating Cash Flow: -13429000 Open source Capital Expenditure: 635000 Open source
20202020-12-31	Free cash flow margin	-430.3%	Revenue: 8779000 Open source Operating Cash Flow: -34988000 Open source Capital Expenditure: 2788000 Open source

Operating cash flow

Cash generated by the company’s normal business operations.

USD -35M 2020

Values and sources

Operating cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20192019-12-31	Operating cash flow	-13429000	Operating Cash Flow: -13429000 Open source
20202020-12-31	Operating cash flow	-34988000	Operating Cash Flow: -34988000 Open source

Free cash flow

Operating cash flow minus capital expenditure for the same period and unit.

USD -37.8M 2020

Values and sources

Free cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20192019-12-31	Free cash flow	-14064000	Operating Cash Flow: -13429000 Open source Capital Expenditure: 635000 Open source
20202020-12-31	Free cash flow	-37776000	Operating Cash Flow: -34988000 Open source Capital Expenditure: 2788000 Open source

Balance sheet

Liabilities and short-term ability to meet obligations at each period end.

Liabilities to assets

Total liabilities as a share of total assets.

5.8% 2020

Values and sources

Liabilities to assets values and source evidence
Period	Series	Value	Source evidence
20192019-12-31	Liabilities / assets	80.1%	Total Liabilities: 16841000 Open source Total Assets: 21019000 Open source
20202020-12-31	Liabilities / assets	5.8%	Total Liabilities: 13134000 Open source Total Assets: 227864000 Open source

Current assets to current liabilities

Current assets divided by current liabilities.

25.29× 2020

Values and sources

Current assets to current liabilities values and source evidence
Period	Series	Value	Source evidence
20192019-12-31	Current assets / current liabilities	2.84×	Current Assets: 19965000 Open source Current Liabilities: 7027000 Open source
20202020-12-31	Current assets / current liabilities	25.29×	Current Assets: 223939000 Open source Current Liabilities: 8856000 Open source

Cash generation

Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.

Cash generation by annual reporting period
Period	Net income	Operating cash flow	Capital expenditure	Free cash flow
2019 2019-01-01 – 2019-12-31	−USD 21.88 million Exact value Exact value: -21877000 USD 2019-01-01 – 2019-12-31: -21877000 USD Inspect Net Income Open source Share or cite Citation for Net Income · PANDION THERAPEUTICS, INC. · 2019-12-31 PANDION THERAPEUTICS, INC. (edgar:1807901) Net Income: -21877000 USD Concept: fundies:NetIncome Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T11:36:18Z Snapshot: 1432ffc521b4693c9c45bf2e8bd12bb6a43540b1617f7c3516e4ba0de06096a1 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1807901/explain?concept=fundies%3ANetIncome&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:NetIncome: -21877000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1807901/000156459021012895/pand-20201231.xml#155154 Filing: 000156459021012895 The citation records this snapshot. The page link may show a newer release later.	−USD 13.43 million Exact value Exact value: -13429000 USD 2019-01-01 – 2019-12-31: -13429000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · PANDION THERAPEUTICS, INC. · 2019-12-31 PANDION THERAPEUTICS, INC. (edgar:1807901) Operating Cash Flow: -13429000 USD Concept: fundies:OperatingCashFlow Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T11:36:18Z Snapshot: 1432ffc521b4693c9c45bf2e8bd12bb6a43540b1617f7c3516e4ba0de06096a1 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1807901/explain?concept=fundies%3AOperatingCashFlow&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -13429000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1807901/000156459021012895/pand-20201231.xml#181327 Filing: 000156459021012895 The citation records this snapshot. The page link may show a newer release later.	USD 635,000 Exact value Exact value: 635000 USD 2019-01-01 – 2019-12-31: 635000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · PANDION THERAPEUTICS, INC. · 2019-12-31 PANDION THERAPEUTICS, INC. (edgar:1807901) Capital Expenditure: 635000 USD Concept: fundies:CapitalExpenditure Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T11:36:18Z Snapshot: 1432ffc521b4693c9c45bf2e8bd12bb6a43540b1617f7c3516e4ba0de06096a1 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1807901/explain?concept=fundies%3ACapitalExpenditure&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 635000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1807901/000156459021012895/pand-20201231.xml#181749 Filing: 000156459021012895 The citation records this snapshot. The page link may show a newer release later.	−USD 14.06 million Calculation and evidence -13429000 − 635000 USD Exact free cash flow: -14064000 USD 2019-01-01 – 2019-12-31: -13429000 USD · Inspect Operating Cash Flow · Source 2019-01-01 – 2019-12-31: 635000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · PANDION THERAPEUTICS, INC. · 2019-12-31 PANDION THERAPEUTICS, INC. (edgar:1807901) Free cash flow: -14064000 USD Concept: free-cash-flow Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T11:36:18Z Snapshot: 1432ffc521b4693c9c45bf2e8bd12bb6a43540b1617f7c3516e4ba0de06096a1 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1807901?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -13429000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1807901/000156459021012895/pand-20201231.xml#181327 Filing: 000156459021012895 Input fundies:CapitalExpenditure: 635000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1807901/000156459021012895/pand-20201231.xml#181749 Filing: 000156459021012895 The citation records this snapshot. The page link may show a newer release later.
2020 2020-01-01 – 2020-12-31	−USD 38.11 million Exact value Exact value: -38105000 USD 2020-01-01 – 2020-12-31: -38105000 USD Inspect Net Income Open source Share or cite Citation for Net Income · PANDION THERAPEUTICS, INC. · 2020-12-31 PANDION THERAPEUTICS, INC. (edgar:1807901) Net Income: -38105000 USD Concept: fundies:NetIncome Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T11:36:18Z Snapshot: 1432ffc521b4693c9c45bf2e8bd12bb6a43540b1617f7c3516e4ba0de06096a1 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1807901/explain?concept=fundies%3ANetIncome&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:NetIncome: -38105000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1807901/000156459021012895/pand-20201231.xml#155000 Filing: 000156459021012895 The citation records this snapshot. The page link may show a newer release later.	−USD 34.99 million Exact value Exact value: -34988000 USD 2020-01-01 – 2020-12-31: -34988000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · PANDION THERAPEUTICS, INC. · 2020-12-31 PANDION THERAPEUTICS, INC. (edgar:1807901) Operating Cash Flow: -34988000 USD Concept: fundies:OperatingCashFlow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T11:36:18Z Snapshot: 1432ffc521b4693c9c45bf2e8bd12bb6a43540b1617f7c3516e4ba0de06096a1 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1807901/explain?concept=fundies%3AOperatingCashFlow&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -34988000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1807901/000156459021012895/pand-20201231.xml#181115 Filing: 000156459021012895 The citation records this snapshot. The page link may show a newer release later.	USD 2.79 million Exact value Exact value: 2788000 USD 2020-01-01 – 2020-12-31: 2788000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · PANDION THERAPEUTICS, INC. · 2020-12-31 PANDION THERAPEUTICS, INC. (edgar:1807901) Capital Expenditure: 2788000 USD Concept: fundies:CapitalExpenditure Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T11:36:18Z Snapshot: 1432ffc521b4693c9c45bf2e8bd12bb6a43540b1617f7c3516e4ba0de06096a1 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1807901/explain?concept=fundies%3ACapitalExpenditure&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 2788000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1807901/000156459021012895/pand-20201231.xml#181539 Filing: 000156459021012895 The citation records this snapshot. The page link may show a newer release later.	−USD 37.78 million Calculation and evidence -34988000 − 2788000 USD Exact free cash flow: -37776000 USD 2020-01-01 – 2020-12-31: -34988000 USD · Inspect Operating Cash Flow · Source 2020-01-01 – 2020-12-31: 2788000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · PANDION THERAPEUTICS, INC. · 2020-12-31 PANDION THERAPEUTICS, INC. (edgar:1807901) Free cash flow: -37776000 USD Concept: free-cash-flow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T11:36:18Z Snapshot: 1432ffc521b4693c9c45bf2e8bd12bb6a43540b1617f7c3516e4ba0de06096a1 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1807901?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -34988000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1807901/000156459021012895/pand-20201231.xml#181115 Filing: 000156459021012895 Input fundies:CapitalExpenditure: 2788000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1807901/000156459021012895/pand-20201231.xml#181539 Filing: 000156459021012895 The citation records this snapshot. The page link may show a newer release later.

Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.

Dataset coverage and company identifiers

Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.

5 filings · 255 latest values · 255 originally reported values

Dataset published 2026-11-02. Source filing dates and reporting periods are shown separately.

Identifiers: 0001807901, 1807901, PAND, edgar:1807901

Also known as PANDION THERAPEUTICS, INC., Pandion Therapeutics Holdco LLC, Pandion Therapeutics, Inc.

PANDION THERAPEUTICS, INC.

Latest quarter

Revenue

Operating margin

Operating cash flow

Free cash flow

Reported share-count change

Company performance

What changed year over year

Revenue

Net income

Operating cash flow

Capital expenditure

Where revenue goes

2020 2020-01-01 – 2020-12-31

Cash

Share of revenue by period

Growth

Profit and cash

Balance sheet

Cash generation